Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Jul;46(1):109–116. doi: 10.1038/bjc.1982.172

Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

D G Hirst, J M Brown, J L Hazlehurst
PMCID: PMC2011076  PMID: 7201845

Abstract

Enhancement of CCNU cytotoxicity by misonidazole (MISO) was studied in three tumours and two normal tissues in the mouse. The 3 experimental tumours (SCCVII/St, EMT6 and KHT) showed very different sensitivities to CCNU alone, but MISO enhanced the cell killing in ech case. The effect was not always dose-modifying, so that the CCNU dose range for the greatest enhancement was different in each of the tumours. In all 3 tumours, enhancement increased with dose of MISO. The effect on two normal tissues, marrow (CFU-S) and testis (spermatogonia), was also investigated. Enhancement of marrow toxicity could be demonstrated only at CCNU doses greater than 12.5 mg/kg, so that at lower CCNU doses there was a therapeutic gain equal to the tumour enhancement ratio. The spermatogonia effect, however, showed enhancement by MISO similar to that seen in the tumours at all CCNU doses up to 20 mg/kg.

Full text

PDF
109

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barranco S. C., Novak J. K., Humphrey R. M. Studies on recovery from chemically induced damage in mammalian cells. Cancer Res. 1975 May;35(5):1194–1204. [PubMed] [Google Scholar]
  2. Brown J. M., Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980 Apr;82(1):171–190. [PubMed] [Google Scholar]
  3. Brown J. M., Yu N. Y., Brown D. M., Lee W. W. SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):695–703. doi: 10.1016/0360-3016(81)90460-0. [DOI] [PubMed] [Google Scholar]
  4. Clement J. J., Gorman M. S., Wodinsky I., Catane R., Johnson R. K. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res. 1980 Nov;40(11):4165–4172. [PubMed] [Google Scholar]
  5. Ewig R. A., Kohn K. W. DNA-protein cross-linking and DNA interstrand cross-linking by haloethylnitrosoureas in L1210 cells. Cancer Res. 1978 Oct;38(10):3197–3203. [PubMed] [Google Scholar]
  6. Kallman R. F., Silini G., Van Putten L. M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst. 1967 Sep;39(3):539–549. [PubMed] [Google Scholar]
  7. Law M. P., Hirst D. G., Brown J. M. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide. Br J Cancer. 1981 Aug;44(2):208–218. doi: 10.1038/bjc.1981.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lu C. C., Meistrich M. L. Cytotoxic effects of chemotherapeutic drugs on mouse testis cells. Cancer Res. 1979 Sep;39(9):3575–3582. [PubMed] [Google Scholar]
  9. Martin W. M., McNally N. J., De Ronde J. Enhancement of the effect of cytotoxic drugs by radiosensitizers. Br J Cancer. 1981 Jun;43(6):756–766. doi: 10.1038/bjc.1981.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Meistrich M. L., Hunter N. R., Suzuki N., Trostle P. K., Withers H. R. Gradual regeneration of mouse testicular stem cells after exposure to ionizing radiation. Radiat Res. 1978 May;74(2):349–362. [PubMed] [Google Scholar]
  11. Mulcahy R. T., Siemann D. W., Sutherland R. M. In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU. Br J Cancer. 1981 Jan;43(1):93–99. doi: 10.1038/bjc.1981.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. OAKBERG E. F. Duration of spermatogenesis in the mouse and timing of stages of the cycle of the seminiferous epithelium. Am J Anat. 1956 Nov;99(3):507–516. doi: 10.1002/aja.1000990307. [DOI] [PubMed] [Google Scholar]
  13. Siemann D. W. In vivo combination of misonidazole and the chemotherapeutic agent CCNU. Br J Cancer. 1981 Mar;43(3):367–377. doi: 10.1038/bjc.1981.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Stephens T. C., Courtenay V. D., Mills J., Peacock J. H., Rose C. M., Spooner D. Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole. Br J Cancer. 1981 Apr;43(4):451–457. doi: 10.1038/bjc.1981.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. TILL J. E., McCULLOCH E. A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961 Feb;14:213–222. [PubMed] [Google Scholar]
  16. Tannock I. F. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer. 1980 Dec;42(6):871–880. doi: 10.1038/bjc.1980.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Twentyman P. R. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. Br J Cancer. 1981 Jun;43(6):745–755. doi: 10.1038/bjc.1981.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Workman P., Brown J. M. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol. 1981;6(1):39–49. doi: 10.1007/BF00253009. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES